Abstract
Tobacco-Free Ireland (TFI) policy sets a tobacco endgame goal to reduce smoking prevalence to less than 5% by 2025. However, public opinion on this goal, an important policy lever, is uncharted in Ireland. This study aimed to inform policy planning by measuring public knowledge and attitudes to tobacco endgame.
A telephone-administered cross-sectional survey of 1,000 randomly-dialled members of the general public was conducted. Prevalence of awareness, perceived achievability, and support for the TFI goal and potential tobacco endgame measures was calculated and compared across tobacco/e-cigarette user status. Logistic regression identified factors independently associated with TFI goal support.
Although TFI goal awareness was low (34.0%), support was high (74.6%), albeit most (60.2%) believed it achievable beyond 2025. Goal support was higher among non-tobacco/e-cigarette users (adjusted Odds Ratio (aOR) 2.68, 95%CI 1.83-3.90), women (aOR 1.55, 95%CI 1.13-2.14) and higher social class members (aOR 1.48, 95%CI 1.03-2.12). Product-focused measures were popular while views on user-focused measures were mixed: e.g. 86.1% supported nicotine content reduction while 40.3% supported user licensing. Phasing-out tobacco sales was highly-supported (82.8%); however, for most, this was contingent on support for currently addicted users.
Despite low awareness, there is strong support for tobacco endgame in Ireland and views on achievability are more realistic than the current goal of 2025. Supporting currently addicted tobacco users and engaging groups with lower support will be important policy planning and communication considerations. The Irish public are ready for tobacco endgame. These findings should re-invigorate policy planning to translate endgame ambition into action.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The fieldwork for the survey was funded by the Health Service Executive Tobacco-Free Ireland Programme
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study involved human participants and was approved by RCPI Ethics Committee (RECAP 157). Participants gave informed consent to participate in the study before taking part.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors
